Lopinavir/r versus nelfinavir as salvage therapy [5]

Pediatric Infectious Disease Journal

Volumn 24, Issue 4, 2005, Pages 392-393

  Resino, Salvador ^a   Alvaro Meca, Alejandro ^a   De José, Maria Isabel ^b   Gurbindo, Maria Dolores ^a   Ramos, José Tomás ^c   Martin Fontelos, Pablo ^b   Muñoz Fernández, Maria Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR;

DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; SALVAGE THERAPY; STATISTICAL ANALYSIS; TREATMENT FAILURE; VIRUS LOAD;

CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; NELFINAVIR; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; VIRAL LOAD;

EID: 17144394060     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000157922.19139.90     Document Type: Letter

References (6)

1. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society: USA Panel. JAMA. 1998;279:1984-1991.
2. Gulick R. When to switch and what to switch to: strategic use of antiretroviral therapy. AIDS Read. 2000;10:156-161; discussion 71-74.
3. Resino S, Bellón JM, Ramos JT, et al. Positive virologic outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study. J Antimicrob Chemother. 2004;54:921-931.
4. Vavro CL, Zimmermmann AM, McClernon DR, et al. Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy. Ann NY Acad Sci. 2000; 918:381-385.
5. Resino S, Bellón JM, Ramos JT, et al. Salvage antiretroviral therapy in HIV-infected children: advantages of lopinavir-ritonavir. Pediatr Infect Dis J. 2004;23:923-930.
6. + T cells response to HAART in HIV-infected children: an observational study. Clin Infect Dis. 2003;37:1216-1225.